Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares RepurchasedShort-Term Debt repayments
Ratios

SRx Health Solutions (SRXH) EBIAT (2016 - 2025)

SRx Health Solutions (SRXH) has disclosed EBIAT for 16 consecutive years, with -$29.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBIAT fell 1220.76% year-over-year to -$29.7 million, compared with a TTM value of -$33.2 million through Jun 2025, down 101.03%, and an annual FY2024 reading of $4.2 million, up 118.41% over the prior year.
  • EBIAT was -$29.7 million for Q2 2025 at SRx Health Solutions, down from -$964000.0 in the prior quarter.
  • Across five years, EBIAT topped out at $24.8 million in Q2 2021 and bottomed at -$29.7 million in Q2 2025.
  • Average EBIAT over 5 years is -$5.1 million, with a median of -$3.7 million recorded in 2023.
  • The sharpest move saw EBIAT skyrocketed 234.62% in 2021, then crashed 1220.76% in 2025.
  • Year by year, EBIAT stood at -$5.1 million in 2021, then tumbled by 379.28% to -$24.4 million in 2022, then skyrocketed by 39.66% to -$14.7 million in 2023, then soared by 72.91% to -$4.0 million in 2024, then crashed by 646.8% to -$29.7 million in 2025.
  • Business Quant data shows EBIAT for SRXH at -$29.7 million in Q2 2025, -$964000.0 in Q1 2025, and -$4.0 million in Q4 2024.